Table 1. Clinical characteristics and scores on the sleep-related questionnaires.
| Control (A) | RLS baseline (B) | RLS follow-up (C) | p | |||
|---|---|---|---|---|---|---|
| A vs. B* | B vs. C† | A vs. C‡ | ||||
| Clinical characteristic | ||||||
| n | 16 | 12 | - | - | ||
| Age (years) | 48.38±9.04 | 47.92±9.41 | 48.00±9.28 | 0.982 | 0.906 | 0.945 |
| Sex, F/M | 15/1 | 11/1 | - | - | - | |
| IRLS score | - | 29.92±4.98 | 13.50±10.94 | - | 0.028 | - |
| BDI-II | 7.44±5.33 | 15.42±9.11 | 8.92±5.87 | 0.017 | 0.084 | 0.568 |
| Treatment with pramipexole | ||||||
| Period (weeks) | - | 12 | - | - | - | |
| Dosage (mg/day) | - | 0.28±0.32 | - | - | - | |
| Sleep-related questionnaires | ||||||
| ISI | 2.88±1.93 | 17.75±6.66 | 10.33±5.69 | <0.001 | 0.019 | <0.001 |
| PSQI | 4.25±1.77 | 13.58±6.46 | 10.08±4.06 | <0.001 | 0.168 | <0.001 |
Data are mean±standard deviation values.
*Control vs. RLS baseline in Mann-Whitney U-tests, †RLS baseline vs. RLS follow-up in Wilcoxon signed-rank tests, ‡Control vs. RLS follow-up in Mann-Whitney U-tests.
BDI-II: Beck Depression Inventory-II, F: female, IRLS: International Restless Legs Syndrome Severity Scale, ISI: Insomnia Severity Index, M: male, PSQI: Pittsburgh Sleep Quality Index, RLS: restless legs syndrome.